IMMUNOCORE
Immunocore is focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The company’s expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems. Immunocore is a biotechnology company that specializes in the development of TCR bispecific immunotherapies.
IMMUNOCORE
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2008-01-01
Address:
Abingdon, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.immunocore.com
Total Employee:
251+
Status:
Active
Contact:
+4401235438600
Total Funding:
808.83 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Google Tag Manager Font Awesome Apache Mobile Non Scaleable Content
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
General Atlantic
General Atlantic investment in Post-IPO Equity - Immunocore
RTW Investments LLC
RTW Investments LLC investment in Post-IPO Equity - Immunocore
Rock Springs Capital
Rock Springs Capital investment in Post-IPO Equity - Immunocore
Oxford Finance LLC
Oxford Finance LLC investment in Debt Financing - Immunocore
BlackRock
BlackRock investment in Series C - Immunocore
RTW Investments LLC
RTW Investments LLC investment in Series B - Immunocore
Terra Magnum Capital Partners (""""TMCP"""")""
Terra Magnum Capital Partners (""""TMCP"""")"" investment in Series B - Immunocore
General Atlantic
General Atlantic investment in Series B - Immunocore
Rock Springs Capital
Rock Springs Capital investment in Series B - Immunocore
JDRF T1D Fund
JDRF T1D Fund investment in Series B - Immunocore
Key Employee Changes
| Date | New article |
|---|---|
| 2020-05-06 | Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy |
Official Site Inspections
http://www.immunocore.com Semrush global rank: 1.62 M Semrush visits lastest month: 15.55 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Immunocore"
Immunocore Holdings plc (IMCR)
Dec 17, 2024 If you are a medical professional and would like further information about Immunocore, our clinical research or clinical trials, please send an email to [email protected] (US) or …See details»
Management team - Immunocore Holdings plc (IMCR)
Prior to Immunocore, Tina was Chief Human Resources Officer at GW Pharmaceuticals and led the company’s transition following its acquisition by Jazz Pharmaceuticals. Tina gained significant experience in HR working across …See details»
Immunocore - Wikipedia
Immunocore was founded in 2008 as a spinout of MediGene AG, which acquired Avidex in 2006. The core technology was spun out of Oxford University in 1999 by Bent Jakobsen into Avidex Ltd. In July 2015, Immunocore announced the completion of an initial $320 million private financing round, Europe's largest ever financing round by a private life sciences company. Fidelity Management & Research Company, Woodford Investment Management, Malin Corporation, El…See details»
Investors :: Immunocore Holdings plc (IMCR)
Nov 6, 2024 If you are a medical professional and would like further information about Immunocore, our clinical research or clinical trials, please send an email to [email protected] (US) or …See details»
Immunocore - Crunchbase Company Profile & Funding
Immunocore is focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The company’s expertise in engineering T Cell Receptors …See details»
Immunocore - Overview, News & Similar companies | ZoomInfo.com
Who is Immunocore. Founded in 2008, Immunocore Limited is a privately owned British clinical-stage biotechnology company. It develops biological drugs to treat cancer , infectious …See details»
Immunocore - Company Profile - Tracxn
Oct 22, 2024 Immunocore - Developer of drugs based on T-Cell receptor technology for the treatment of cancer. Public Company. Raised a total funding of $525M over 7 rounds from 22 …See details»
Immunocore Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Immatics, as well as Immunocore, are also developing bispecific antibodies targeted at PRAME. Cell Therapy Phase 3 Immunotherapy Clinical Result Phase 1. ... The statistics for drugs in the …See details»
Immunocore Company Profile - Craft
Oct 29, 2024 Immunocore has 5 employees across 3 locations and $249.43 m in annual revenue in FY 2023. See insights on Immunocore including office locations, competitors, …See details»
Member profile: Immunocore Limited | BIA - bioindustry.org
Dec 9, 2024 Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy. …See details»
Corporate Governance :: Immunocore Holdings plc (IMCR)
Professor Sir John Bell was appointed to the Immunocore Board in March 2015. Professor Bell is the Regius Professor of Medicine at Oxford University and Chairman of the Office for the …See details»
Immunocore Holdings plc (IMCR): history, ownership, mission
Nov 16, 2024 [relinking] Home History Owners Mission How It Works How It Makes Money Immunocore Holdings plc (IMCR) Information A Brief History of Immunocore Holdings plc …See details»
A Brief History of Immunocore – CANVAS, SWOT, PESTEL & BCG …
Oct 2, 2024 A Brief History of Immunocore: Founded in 2008, Immunocore is a pioneering biotechnology company focused on developing novel T cell receptor-based therapeutics for …See details»
Immunocore - Contacts, Employees, Board Members, Advisors
Organization. Immunocore . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Number of Board …See details»
Immunocore - Overview, News & Similar companies | ZoomInfo.com
Immunocore opens up its US office in Philadelphia. IMCgp100 is accepted for the EMA's adaptive pathway pilot programme for treatment of metastatic uveal melanoma, a rare and fatal disease …See details»
Immunocore appoints Travis Coy as CFO and Head of Corporate
1 day ago Immunocore (IMCR) has appointed Travis Coy as EVP, CFO and Head of Corporate Development, effective January 1. He will become an Executive Officer, transitioning from his …See details»
Compliance and Transparency :: Immunocore Holdings plc (IMCR)
Immunocore Ltd is committed to lawful and ethical business operations, including adhering to all applicable laws, regulations, and codes of the countries in which it operates. ... Immunocore …See details»
Immunocore Appoints Travis Coy as EVP, Chief Financial Officer
3 days ago Immunocore Holdings plc has appointed Travis Coy as Executive Vice President, Chief Financial Officer, and Head of Corporate Development effective January 1, 2025. Coy, …See details»
Immunocore Names Non-Executive Board Member as CFO
1 day ago Immunocore Holdings hired a non-executive director on its board as the company's chief financial officer. The U.K. biotechnology company Thursday said Travis Coy has been …See details»
Careers - Immunocore Holdings plc (IMCR)
The obtaining of prior written authorization is a condition precedent to any agreement (verbal or written) between the recruitment organization and Immunocore. In the absence of such written …See details»